Scarica l'app Stockscreener
58.51
0.95%
-0.56
Biomarin Pharmaceutical Inc Borsa (BMRN) Ultime notizie
Is It Time To Reassess BioMarin Pharmaceutical (BMRN) After Prolonged Share Price Weakness - simplywall.st
Early VOXZOGO Data May Reshape BioMarin Growth Expectations In Achondroplasia - Sahm
BioMarin outlines 2025 revenue growth with VOXZOGO expected to reach $950M - MSN
BioMarin Pharmaceutical (BMRN) Receives FDA Approval for Expanded Use of PALYNZIQ in Adolescents - Insider Monkey
Inflation Data: What is the target price for BioMarin Pharmaceutical Inc stock2026 Trends & Technical Pattern Based Signals - baoquankhu1.vn
EVP Of BioMarin Pharmaceutical Sold $996K In Stock - Benzinga
Jefferies Maintains Buy on BioMarin Pharmaceutical Inc. (BMRN) March 2026 - Meyka
BioMarin Pharmaceutical Highlights Growth Plan, VOXZOGO Milestones, and Amicus Deal at Conference - Yahoo Finance
BioMarin reports growth data for achondroplasia drug VOXZOGO - Investing.com South Africa
BioMarin reports growth data for achondroplasia drug VOXZOGO By Investing.com - Investing.com Nigeria
Jefferies reiterates Buy on BioMarin stock after DMD trial data - Investing.com UK
Jefferies reiterates Buy on BioMarin stock after DMD trial data By Investing.com - Investing.com Canada
BioMarin Presents New Data on the Positive Impact of Early Treatment With VOXZOGO® (vosoritide) on Proportionality and Arm Span in Children with Achondroplasia at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical - PR Newswire
First Trust Advisors LP Raises Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Capital Research Global Investors Purchases 2,145,717 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Dimensional Fund Advisors LP Purchases 671,566 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BofA cuts BioMarin stock price target to $85 on Voxzogo outlook - Investing.com UK
BMRN: Strong 2025 growth, major 2026 clinical milestones, and Amicus acquisition drive future outlook - TradingView
BMRN: Strong 2025 growth, Amicus acquisition, and key 2026 clinical milestones drive optimism - TradingView
Uniqure To Rally Around 92%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga
BioMarin Pharmaceutical (NASDAQ:BMRN) Given New $85.00 Price Target at Bank of America - MarketBeat
PALYNZIQ Pediatric Label Expansion Under REMS Might Change The Case For Investing In BioMarin (BMRN) - simplywall.st
BridgeBio's Rare-Disease Pipeline Sparks Growth Buzz - Benzinga
BioMarin Pharmaceutical Inc. $BMRN Shares Bought by Korea Investment CORP - MarketBeat
Leerink Maintains Market Perform on BioMarin (BMRN) March 09, 2026 - Meyka
Leerink Partners reiterates Market Perform on BioMarin stock at $62 By Investing.com - Investing.com Australia
Leerink Partners reiterates Market Perform on BioMarin stock at $62 - Investing.com
Are Options Traders Aware of Insights on BMRN Stock That We Might Not Know? - Bitget
Do Options Traders Know Something About BMRN Stock We Don't? - Yahoo Finance
Earnings Beat: Is BioMarin Pharmaceutical Inc stock a value trapStop Loss & Technical Confirmation Trade Alerts - baoquankhu1.vn
BMRN: Strong 2025 growth, major pipeline milestones, and Amicus acquisition set to drive future value - TradingView
BMRN: Strong 2025 growth, robust pipeline, and Amicus acquisition set stage for future expansion - TradingView
WINTON GROUP Ltd Has $6.69 Million Stake in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin Pharmaceutical Inc. $BMRN Position Boosted by Vinva Investment Management Ltd - MarketBeat
Assessing BioMarin Pharmaceutical (BMRN) Valuation After FDA Expands PALYNZIQ Label For Pediatric PKU - Sahm
Rhenman & Partners Asset Management Boosts BioMarin Pharmaceutical Holdings - National Today
Rhenman & Partners Asset Management AB Has $10.11 Million Stock Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Crossmark Global Holdings Inc. Has $4.02 Million Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Why BioMarin Pharmaceutical Inc. stock could see breakout soonEarnings Performance Report & Stepwise Trade Signal Implementation - Naître et grandir
Fisher Asset Management LLC Has $1.72 Million Stock Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin Pharmaceutical Details Strategy Refresh, Voxzogo Competition and 40% Margin Goal at TD Cowen Confab - MarketBeat
Morgan Stanley Sees Rebound Potential in BioMarin (BMRN), Highlights Underappreciated Voxzogo Upside - MSN
(BMRN) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
FDA Extends Approval of PKU Drug to Include Adolescents - Medscape
Skeletal Dysplasia Market - GlobeNewswire Inc.
BioMarin Pharma: The Under-Two Strategy and New Market Ramps Shaping Voxzogo’s Next Chapter! - Smartkarma
Global Orphan Drugs Market is Anticipated to Cross USD 350 Billion by 2032 | DelveInsight - Bolsamania
BioMarin Strengthens PKU Portfolio With FDA Approval For Younger Patients - AOL.com
Elo Mutual Pension Insurance Co Boosts BioMarin Pharmaceutical Holdings - National Today
Elo Mutual Pension Insurance Co Purchases 22,851 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Barclays raises BioMarin stock price target to $105 on acquisition By Investing.com - Investing.com UK
Amicus Therapeutics shareholders approve acquisition by BioMarin Pharmaceutical - Investing.com
Shareholders back Amicus (NASDAQ: FOLD) sale to BioMarin Pharmaceutical - Stock Titan
The kids are alright: Old drug from BioMarin scores key win in teensSan Francisco Business Times - The Business Journals
Barclays raises BioMarin stock price target to $105 on acquisition - Investing.com
Truist reiterates Buy on BioMarin stock amid new competition - Investing.com India
BioMarin Pharmaceutical Holdings Reduced by Rafferty Asset Management - National Today
Truist reiterates Buy on BioMarin stock amid new competition By Investing.com - Investing.com Nigeria
BioMarin stock price target raised to $105 by Freedom Capital on margin outlook - Investing.com Nigeria
Ascendis gains more altitude with FDA approval for dwarfism drug Yuviwel - Fierce Pharma
Cantor Fitzgerald reiterates Overweight on BioMarin stock at $85 - Investing.com
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):